Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 6

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 6
---
, you should also read the entire prospectus supplement and the accompanying base prospectus carefully, including the “Risk Factors” sections of this prospectus supplement and the accompanying base prospectus, and the financial statements and related notes included or incorporated by reference in this prospectus supplement and the accompanying base prospectus.

References in this prospectus supplement to “Armata,” the “Company,” “we,” “us” and “our” refer to Armata Pharmaceuticals, Inc. and its subsidiaries, on a consolidated basis, unless the context requires otherwise.

Our Company

We are a clinical-stage biotechnology company
focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and
difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We have completed three Phase 2 clinical
trials to date. We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the
growing bacterial resistance to current classes of antibiotics. Bacteriophages or “phages” have a powerful and highly differentiated
mechanism of action that enables binding to and killing of specific targeted bacteria while uniquely preserving the normal human microbiome
or “healthy bacteria”. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome
increasing susceptibility to opportunistic pathogens, such as Clostridium difficile. We believe that phages represent a promising
means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial
infections resistant to current standard of care therapies, including the multidrug-resistant or “superbug” strains of bacteria.
We are a leading developer of clinical-stage phage therapeutics of high purity, and believe we are uniquely positioned to address the
growing worldwide threat of antibiotic-resistant bacterial infections.

We are combining our proprietary approach and
expertise in identifying, characterizing and developing both naturally occurring and engineered (synthetic) bacteriophages with our proprietary
phage-specific host-engineered current Good Manufacturing Practices (“cGMP”) manufacturing capabilities to advance a target
pipeline of high-quality bacteriophage product candidates for late-stage clinical development. Our optimized manufacturing processes significantly
increase phage titers and improve production efficiency with the goal of ensuring commercial viability.

We remain committed to our mission to evaluate
phage-based therapeutics in randomized controlled clinical trials that evaluate safety and efficacy required to support potential regulatory
approval and commercialization of our phage products